United Therapeutics director sells 228 shares
Director Nilda Mesa exercised options and sold 228 UTHR shares on September 14, 2026 in open-market style transactions not reported under a Rule 10b5-1 plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp (UTHR) director Nilda Mesa exercised stock options for 130 shares of common stock on September 14, 2026 at an exercise price of $110.86 per share, then sold a total of 228 shares in two transactions at prices around $505.8 per share. Following the option exercise, she held 6,430 stock options directly, and no transactions were reported under a Rule 10b5-1 trading plan.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Mesa Nilda
Role
Director
Sold
228 shs ($115K)
Approx. gross sale proceeds
$115K
Approx. exercise cost
$14K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 130 | $0.00 | $0.00 |
| Exercise | Common Stock | 130 | $110.86 | $14K |
| Sale | Common Stock F1 | 130 | $505.7868 | $66K |
| Sale | Common Stock | 98 | $505.975 | $50K |
Holdings After Transaction:
Stock Option — 6,430 contracts (Direct);
Common Stock — 5,580 shares (Direct)
Footnotes (1)
- F1. This transaction was executed in multiple trades at prices ranging from $505.76 to $505.985. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 130 shares
Exercise price: $110.86 per share
Shares sold (total): 228 shares
+4 more
7 metrics
Options exercised
130 shares
Stock options for UNITED THERAPEUTICS common stock exercised on September 14, 2026
Exercise price
$110.86 per share
Exercise price of stock options converted into 130 shares of common stock
Shares sold (total)
228 shares
Common stock sales on September 14, 2026
Sale price (weighted average)
$505.7868 per share
Weighted average price for 130-share sale, with trades between $505.76 and $505.985
Sale price (second trade)
$505.9750 per share
Price for 98-share common stock sale on September 14, 2026
Options held after transaction
6,430 options
Total stock options following the reported option exercise
Option expiration date
October 31, 2028
Expiration date of the stock options exercised for 130 shares
Key Terms
derivative security, weighted average price, Rule 10b5-1 trading plan, exercise price
4 terms
derivative security financial
"described as an exercise or conversion of a derivative security into common stock"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 trading plan regulatory
"No transactions in this Form 4 are reported under a Rule 10b5-1 trading plan."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
exercise price financial
"exercised stock options at an exercise price of $110.86 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did UTHR director Nilda Mesa report in this Form 4?
She reported exercising stock options for 130 shares of UNITED THERAPEUTICS common stock at an exercise price of $110.86 per share, and selling 228 shares of common stock on September 14, 2026 at prices around $505.8 per share.
At what price were Nilda Mesa’s UTHR options exercised?
She exercised stock options covering 130 shares of UNITED THERAPEUTICS common stock at an exercise price of $110.86 per share. These options were originally granted with an expiration date of October 31, 2028.
How many UNITED THERAPEUTICS options does Nilda Mesa hold after these transactions?
After the option exercise reported in this Form 4, Nilda Mesa directly holds 6,430 stock options for UNITED THERAPEUTICS common stock, as shown in the derivative holdings following the transaction.
Were Nilda Mesa’s UTHR trades under a Rule 10b5-1 trading plan?
No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so these UNITED THERAPEUTICS transactions are not reported as being made under a Rule 10b5-1 trading plan.
What does the footnote say about the UTHR sale price in this Form 4?
For the 130-share sale at $505.7868 per share, the footnote explains that the transaction was executed in multiple trades between $505.76 and $505.985, and that the reported price is a weighted average price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
